Target intelligence / Profile preview

Heat-labile enterotoxin of human enterotoxigenic Escherichia coli (LTh)

Target
LTh
Molecular classification
Bacterial toxin (UniProt P06717), AB5-type toxin (PubMed: 15175434), ADP-ribosyltransferase (PubMed: 15175434), Mucosal adjuvant (PubMed: 28919436)
01

Overview

Heat-labile enterotoxin (LT) is a major virulence factor produced by enterotoxigenic Escherichia coli (ETEC), which is a primary cause of diarrhea in travelers and children in low-income countries (UniProt P06717). The toxin is an AB5-type protein consisting of a catalytic A subunit and a pentameric B subunit that binds to GM1 ganglioside receptors on host cell surfaces (PubMed: 15175434). Detoxified LTh refers to human-derived LT variants, such as LT(R192G) or dLT, which have been genetically engineered to eliminate the ADP-ribosyltransferase activity responsible for toxicity while maintaining potent immunogenic properties (PubMed: 22431647). These detoxified forms are primarily utilized as mucosal adjuvants in vaccine development to stimulate robust secretory IgA and systemic IgG responses against ETEC (PubMed: 28919436). By enhancing the immune system's recognition of co-administered antigens, detoxified LTh plays a critical role in the design of oral vaccines like ETVAX, which aim to provide broad protection against ETEC-mediated disease (ClinicalTrials.gov: NCT02531802).

Other names
LTHeat-labile enterotoxindLTDetoxified heat-labile enterotoxinLT(R192G)LT-K63Escherichia coli heat-labile enterotoxinHuman heat-labile enterotoxin
02

Mechanism of action

The detoxified heat-labile enterotoxin (LTh) acts as a mucosal adjuvant by binding to GM1 ganglioside receptors on intestinal epithelial and immune cells via its B-subunit pentamer (PubMed: 15175434). In its detoxified form, such as the R192G mutant, the A-subunit's ability to ADP-ribosylate the Gs alpha protein is abolished, preventing the elevation of intracellular cAMP and the subsequent diarrheal response (PubMed: 22431647). However, the molecule remains highly immunogenic and facilitates the recruitment and activation of antigen-presenting cells, such as dendritic cells, thereby promoting the induction of both mucosal (IgA) and systemic (IgG) immune responses against co-administered or intrinsic antigens (PubMed: 28919436).

03

Biological functions

Mucosal adjuvanticity (PubMed: 28919436)GM1 ganglioside binding (PubMed: 15175434)Immune response stimulation (PubMed: 28919436)Antigen presentation enhancement (PubMed: 28919436)
04

Disease associations

Enterotoxigenic Escherichia coli (ETEC) infection (PubMed: 15175434)Traveler's diarrhea (PubMed: 15175434)Pediatric diarrhea (PubMed: 15175434)
05

Safety considerations

Bell's palsy (facial nerve paralysis) (PubMed: 11859554)Residual enterotoxicity (PubMed: 22431647)Injection site reactions (PubMed: 28919436)Potential for unintended inflammatory responses (PubMed: 28919436)
06

Interacting drugs

ETVAX (ClinicalTrials.gov: NCT02531802)

3 more in the full profile.

07

Biomarkers

Anti-LT IgA antibody titers (PubMed: 28919436)Anti-LT IgG antibody titers (PubMed: 28919436)Fecal secretory IgA (sIgA) (PubMed: 28919436)LT-specific memory B-cell responses (PubMed: 28919436)

Beyond the preview

Go deeper on Heat-labile enterotoxin of human enterotoxigenic Escherichia coli (LTh).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Heat-labile enterotoxin of human enterotoxigenic Escherichia coli (LTh).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call